Maridebart Cafraglutide and Oral Contraceptives in Postmenopausal Women
This study is looking at how a drug called maridebart cafraglutide affects how your body absorbs and processes combined oral contraceptives (COCs). We are enrolling postmenopausal women, aged 45 to 65, who are living with overweight or obesity (BMI between 25.0 and 38.0 kg/m^2). You must also have a stable body weight. The main goal is to see if maridebart cafraglutide changes the levels of COCs in your body, specifically measuring the maximum concentration (Cmax) and the total amount absorbed over time (AUC). The current status of this study is unclear, and it plans to enroll 49 participants.
- Study design
- This is an interventional study, meaning participants will receive specific treatments. It plans to enroll 49 postmenopausal women.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Measurements of oral contraceptive levels will be taken from Day 1 up to Day 89.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity
At a glance
Conditions
Where it's being run
2 sites across 2 statesStudy leadership
- MD · STUDY_DIRECTOR · Amgen
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Maximum Observed Concentration (Cmax) of COCDay 1 up to Day 89
- Area Under the Concentration-time Curve (AUC) from Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of COCDay 1 up to Day 89
- AUC from Time Zero Extrapolated to Infinity (AUCinf) of COCDay 1 up to Day 89